https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-21 / BMC Cancer 2017 12;17(1):884
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-21 / BMC Cancer 2017 12;17(1):8842017-12-21 00:00:002019-02-15 08:45:44Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-20 / Trends Immunol. 2018 03;39(3):209-221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-20 / Trends Immunol. 2018 03;39(3):209-2212017-12-20 00:00:002019-02-15 09:23:08Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-776
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-7762017-12-12 00:00:002019-02-15 08:50:39Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-756
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-7562017-12-05 00:00:002019-02-15 08:47:38Advances in immunotherapeutic research for glioma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-2961
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-29612017-12-01 00:00:002017-12-01 00:00:00Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
